Modular Medical Announces Licensing and Partnership Agreement With Nudge BG
Modular Medical (NASDAQ:MODD) has announced a licensing and partnership agreement with Nudge BG to develop an adaptive full closed loop Automated Insulin Delivery (AID) system that doesn't require mealtime announcements. The collaboration aims to create a system that automatically manages mealtime insulin delivery, eliminating the need for manual bolusing while maintaining glycemic goals.
The partnership combines Modular Medical's FDA-cleared MODD1 insulin pump with Nudge BG's AID technology, targeting the approximately 80% of potential adopters who find current systems too complex, cumbersome, and costly. The system will make small insulin delivery adjustments based on continuous glucose monitor inputs, making diabetes management less burdensome for users.
Modular Medical (NASDAQ:MODD) ha annunciato un accordo di licenza e partnership con Nudge BG per sviluppare un sistema di somministrazione automatica dell'insulina (AID) completamente chiuso e adattivo, che non richiede annunci relativi ai pasti. La collaborazione mira a creare un sistema che gestisca automaticamente la somministrazione dell'insulina per i pasti, eliminando la necessità di bolus manuali mentre si mantengono gli obiettivi glicemici.
La partnership combina la pompa insulinica MODD1 approvata dalla FDA di Modular Medical con la tecnologia AID di Nudge BG, mirando al circa 80% dei potenziali utenti che trovano i sistemi attuali troppo complessi, ingombranti e costosi. Il sistema effettuerà piccole regolazioni nella somministrazione dell'insulina in base ai dati dei monitor di glucosio continuo, rendendo la gestione del diabete meno gravosa per gli utenti.
Modular Medical (NASDAQ:MODD) ha anunciado un acuerdo de licencia y asociación con Nudge BG para desarrollar un sistema de entrega automática de insulina (AID) completamente cerrado y adaptativo que no requiere anuncios para las comidas. La colaboración tiene como objetivo crear un sistema que gestiona automáticamente la entrega de insulina durante las comidas, eliminando la necesidad de bolas manuales mientras se mantienen los objetivos glucémicos.
La asociación combina la bomba de insulina MODD1, autorizada por la FDA, de Modular Medical con la tecnología AID de Nudge BG, dirigida aproximadamente al 80% de los posibles adoptantes que encuentran los sistemas actuales demasiado complejos, engorrosos y costosos. El sistema realizará pequeños ajustes en la entrega de insulina basándose en las entradas del monitor continuo de glucosa, haciendo que la gestión de la diabetes sea menos onerosa para los usuarios.
모듈러 메디컬 (NASDAQ:MODD)은 Nudge BG와 협력하여 식사 알림이 필요 없는 적응형 완전 폐쇄형 자동 인슐린 전달(AID) 시스템을 개발하기 위한 라이센스 및 파트너십 계약을 발표했습니다. 이번 협력은 수동 볼루스를 없애고 혈당 목표를 유지하면서 자동으로 식사 인슐린 전달을 관리하는 시스템을 만드는 것을 목표로 합니다.
이번 파트너십은 모듈러 메디컬의 FDA 승인을 받은 MODD1 인슐린 펌프와 Nudge BG의 AID 기술을 결합하여 현재 시스템이 너무 복잡하고 번거로우며 비용이 많이 드는 약 80%의 잠재 사용자에게 다가갑니다. 이 시스템은 지속적인 혈당 모니터 입력에 따라 소량의 인슐린 전달 조정을 수행하여 사용자의 당뇨병 관리 부담을 줄입니다.
Modular Medical (NASDAQ:MODD) a annoncé un accord de licence et de partenariat avec Nudge BG pour développer un système de livraison automatique d'insuline (AID) entièrement fermé et adaptatif qui ne nécessite pas d'annonces pour les repas. La collaboration vise à créer un système qui gère automatiquement la livraison de l'insuline au moment des repas, éliminant ainsi le besoin de bolus manuels tout en maintenant les objectifs glycémiques.
Ce partenariat combine la pompe à insuline MODD1, approuvée par la FDA, de Modular Medical avec la technologie AID de Nudge BG, visant les environ 80 % des utilisateurs potentiels qui trouvent les systèmes actuels trop complexes, encombrants et coûteux. Le système effectuera de petits ajustements dans la livraison d'insuline en fonction des entrées du moniteur de glucose continu, rendant la gestion du diabète moins lourde pour les utilisateurs.
Modular Medical (NASDAQ:MODD) hat eine Lizenz- und Partnerschaftsvereinbarung mit Nudge BG bekannt gegeben, um ein adaptives, vollautomatisches Insulinabgabesystem (AID) zu entwickeln, das keine Essensankündigungen erfordert. Die Zusammenarbeit zielt darauf ab, ein System zu schaffen, das die Insulinabgabe zu den Mahlzeiten automatisch verwaltet und die Notwendigkeit manueller Bolusgaben beseitigt, während die glykämischen Ziele beibehalten werden.
Die Partnerschaft kombiniert die von der FDA zugelassene MODD1-Insulinpumpe von Modular Medical mit der AID-Technologie von Nudge BG und richtet sich an die etwa 80 % der potenziellen Anwender, die die aktuellen Systeme als zu komplex, umständlich und kostspielig empfinden. Das System wird kleine Anpassungen bei der Insulindosierung basierend auf den Eingaben des kontinuierlichen Glukosemonitors vornehmen und so das Diabetesmanagement für die Nutzer erleichtern.
- Partnership targets untapped 80% market of potential insulin pump adopters
- Development of simplified AID system eliminating manual mealtime insulin calculations
- Integration with FDA-cleared MODD1 insulin pump technology
- Product still in development phase with no specified timeline for market release
- Will face competition from established players in the AID market
Insights
The partnership between Modular Medical and Nudge BG represents a significant technological advancement in insulin delivery systems. The proposed adaptive full closed loop system addresses a critical market gap by eliminating the need for manual mealtime announcements - a major pain point in current Hybrid Closed Loop systems. Lane Desborough's extensive experience in AID systems, particularly from Bigfoot Biomedical and Medtronic Diabetes, brings valuable expertise to this collaboration.
The MODD1 pump's integration with Nudge BG's technology could potentially capture a significant portion of the untapped 80% market segment of potential pump users who have been hesitant to adopt current solutions. The emphasis on simplicity and automation, combined with MODD1's cost-effective approach, positions this system to potentially disrupt the
This strategic partnership could significantly strengthen Modular Medical's competitive position against established players like Medtronic and Insulet. The focus on the underserved "almost-pumpers" segment with a simplified, automated solution addresses a clear market need. Given Modular Medical's current market cap of
The elimination of carbohydrate counting and manual bolusing requirements removes major adoption barriers in the insulin pump market. For context, similar technological advancements in competing products have historically led to significant market share gains. The partnership with an industry veteran like Desborough adds credibility to the company's execution capability.
The technological differentiation of this full closed loop system lies in its adaptive nature and ability to function without mealtime announcements. This represents a leap forward from current Hybrid Closed Loop systems, potentially offering a more "set-and-forget" solution for diabetes management. The system's design philosophy aligns with the broader healthcare trend toward reducing patient burden while maintaining or improving clinical outcomes.
The integration of continuous glucose monitor data with automated insulin delivery algorithms, especially without requiring manual input, could significantly improve patient compliance and outcomes. This could potentially lead to better insurance coverage and reimbursement rates, critical factors for market adoption in the medical device sector.
-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements
-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG.
"We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery ("AID") to the marketplace," said Lane Desborough, CEO of Nudge BG. "Nudge BG's adaptive full closed loop AID technology, unlike the present Hybrid Closed Loop products, complements Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor."
"We believe most people living with insulin-requiring diabetes find it difficult or impossible to sustain the therapy effort which contemporary AID systems demand, including counting carbohydrates and calculating bolus delivery amounts, preventing them from reaping the benefits of the present technology. It has been the goal of Nudge BG to design an AID system that will truly make the diabetes management experience both effective and less burdensome for users. Our system will fully automate mealtime insulin delivery, freeing people with diabetes from the risk and difficulty of bolusing, while still achieving glycemic goals," said Desborough.
Paul DiPerna, President and CTO of Modular Medical, stated "Our goal at Modular Medical is to bring the benefits of insulin pump technology to the approximately
Mr. Desborough has been developing control algorithms in safety-critical industries for the past 35 years. He was formerly Co-Founder and Chief Engineer of Bigfoot Biomedical and previously served as Chief Engineer, Closed Loop/Insulin Delivery at Medtronic Diabetes. Mr. Desborough has been developing commercial AID systems since 2010, soon after his son was diagnosed with type-1 diabetes.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release. These forward looking statements and factors include, but are not limited to, whether Modular Medical and Nudge BG can successfully bring to market an AID system, the successful integration of Nudge BG's AID technology with Modular Medical's pump products, the anticipated performance and expected benefits of the proposed Modular Medical and Nudge AID system, whether Modular Medical can successfully develop its proprietary technologies, whether the market will accept Modular Medical's products and services, the future product roadmap and development activities, anticipated consumer demand for the Modular Medical's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
About Nudge BG
Nudge BG is an engineering consulting services and algorithm development company focused on modeling, simulation, and control of physiological systems. Nudge BG was founded by Lane Desborough.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on accesswire.com
FAQ
What is the main benefit of MODD's new partnership with Nudge BG?
How does MODD's new AID system differ from current market solutions?
What market segment is MODD targeting with this new AID system?
Who is leading the development of MODD's new automated insulin delivery system?
